Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Next Previous
Trial Profile

A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPLORER-HCM
  • Sponsors MyoKardia

Most Recent Events

  • 27 Mar 2025 According to Bristol Myers Squibb media release, based on the results of this study and the domestic HORIZON-HCM study of Japan, the company has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare- Japan, for Camzyos (mavacamten) capsules 1mg, 2.5mg, and 5mg for the treatment of obstructive hypertrophic cardiomyopathy (HOCM).
  • 08 Apr 2024 Results of exploratory analysis assessing the effect of mavacamten on circulating biomarkers using proteomics presented at the 73rd Annual Scientific Session of the American College of Cardiology
  • 14 Nov 2023 Results of prespecified post hoc analysis from explorer HCM trial assessing baseline clinical and echocardiographic characteristics and response to mavacamten among women compared with men published in the Circulation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top